Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer
Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer
复制标题
DOI：
10.1038/srep30386
复制
发表时间：
2016-08-09
影响因子：
4.6
通讯作者：
Lee, Ji Youl
中科院分区：
文献类型：
--
作者：
Park, Yong Hyun;Shin, Hyun Woo;Lee, Ji Youl
细胞外囊泡（EV）可能在癌症的发生和发展中起重要作用。我们旨在研究前列腺癌（PCa）患者中前列腺特异性EV的预后潜力。血浆和前列腺组织收集自接受PCa（n = 82）或良性前列腺增生（BPH，n = 28）手术的患者。为了分析前列腺中EV的数量，我们进行了透射电子显微镜（TEM），CD 63和前列腺特异性膜抗原（PSMA）的免疫TEM和免疫荧光染色。从血浆中分离EV后，使用ELISA试剂盒测量CD 63和PSMA浓度。前列腺PSMA阳性区域在BPH和低、中、高危PCa患者中存在差异（2.4、8.2、17.5、26.5%，p < 0.001）。血浆PSMA阳性EV浓度在BPH和低、中和高风险PCa患者中不同（21.9、43.4、49.2、59.9 ng/mL，p < 0.001），ROC曲线分析表明血浆PSMA阳性EV浓度区分PCa和BPH（AUC 0.943）。血浆PSMA阳性EV浓度较低的患者具有较大的前列腺体积（50.2对33.4 cc，p < 0.001）和较低的病理学Gleason评分（p = 0.025）。在18个月的中位随访期间，血浆PSMA阳性EV浓度较低的患者比前列腺特异性EV水平较高的患者发生生化衰竭的风险更低（p = 0.085）。
Extracellular vesicles (EVs) may play an important role in cancer development and progression. We aimed to investigate the prognostic potential of prostate-specific EVs in prostate cancer (PCa) patients. Plasma and prostate tissue were collected from patients who underwent surgery for PCa (n = 82) or benign prostatic hyperplasia (BPH, n = 28). To analyze the quantity of EVs in prostate, we performed transmission electron microscopy (TEM), immuno-TEM with CD63 and prostate-specific membrane antigen (PSMA), and immunofluorescence staining. After EV isolation from plasma, CD63 and PSMA concentration was measured using ELISA kits. PSMA-positive areas in prostate differed in patients with BPH, and low-, intermediate-, and high-risk PCa (2.4, 8.2, 17.5, 26.5%, p < 0.001). Plasma PSMA-positive EV concentration differed in patients with BPH, and low-, intermediate-, and high-risk PCa (21.9, 43.4, 49.2, 59.9 ng/mL, p < 0.001), and ROC curve analysis indicated that plasma PSMA-positive EV concentration differentiated PCa from BPH (AUC 0.943). Patients with lower plasma PSMA-positive EV concentration had greater prostate volume (50.2 vs. 33.4 cc, p < 0.001) and lower pathologic Gleason score (p = 0.025). During the median follow-up of 18 months, patients with lower plasma PSMA-positive EV concentration tended to have a lower risk of biochemical failure than those with higher levels of prostate-specific EVs (p = 0.085).